When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

Neuropsychopharmacology

Volumn 34, Issue 10, 2009, Pages 2227-2236

  Perlis, Roy H ^a,d   Patrick, Amanda ^b   Smoller, Jordan W ^a   Wang, Philip S ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cost effectiveness; Major depressive disorder; Pharmacogenetics; Serotonin

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; MIRTAZAPINE; NORTRIPTYLINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG SCREENING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EFFECT SIZE; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; PHARMACOGENETICS; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REMISSION;

ADULT; ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEALTH CARE COSTS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHARMACOGENETICS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SEROTONIN UPTAKE INHIBITORS;

EID: 68949196334     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.50     Document Type: Article

References (55)

1. Agency for Healthcare Research and Quality (2007). Testing for cytochrome p450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evidence report/technology assessment 146. Accessed at www.ahrq.gov/downloads/pub/evidence/pdf/cyp450/ cyp450.pdf. [this is a white paper].
2. Anonymous (2006). Drug Topics Red Book, 108th edn. Medical Economics: Montvale, NJ.
3. Arias E (2004). United States Life Tables. National Center for Health Statistics: Hyattsville, MD.
4. Bennett KJ, Torrance GW, Boyle MH, Guscott R, Moran LA (2000). Development and testing of a utility measure for major, unipolar depression (McSad). Qual Life Res 9: 109-120.
5. Centers for Medicare and Medicaid Services (2004). Physician fee schedule payment amount file national/carrier. Available at http://www.cms.hhs.gov/ PhysicianFeeSched/01-overview.asp. Accessed on 1 October 2007.
6. Fava M (2001). Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 62(Suppl 18): 4-11.
7. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K et al (1993). The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 13: 89-102.
8. Fryback DG, Dunham NC, Palta M, Hanmer J, Buechner J, Cherepanov D et al (2007). US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 45: 1162-1170.
9. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161: 1537-1547.
10. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds) (1996). Cost-Effectiveness in Health and Medicine. Oxford University Press: New York.
11. Grembowski DE, Martin D, Patrick DL, Diehr P, Katon W, Williams B et al (2002). Managed care, access to mental health specialists, and outcomes among primary care patients with depressive symptoms. J Gen Intern Med 17: 258-269.
12. Hamilton S (2007). Pharmacogenetics in Psychiatry meeting. New York, NY.
13. Hsieh MH, Meng MV (2007). Decision analysis and Markov modeling in urology. J Urol 178: 1867-1874.
14. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ et al (2007). Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 64: 783-792.
15. Kaplan RM, Feeny D, Revicki DA (1993). Methods for assessing relative importance in preference based outcome measures. Qual Life Res 2: 467-475.
16. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
17. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ et al (2006). Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 296: 1609-1618.
18. Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D et al (2007). Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 164: 1530-1538.
19. Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992). How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146: 473-481.
20. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L (1992). Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 149: 795-800.
21. McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J et al (2000). Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry 61: 518-524.
22. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF et al (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78: 804-814.
23. National Center for Health Statistics (1998). Vital statistics of the United States, 1995. Volume II, Mortality, Part A, Section 6: life tables. DHHS Publication No (PHS) 98-1147, Hyattsville, MD, US Dept HHS.
24. O'Carroll PW, Berman AL, Maris RW, Moscicki EK, Tanney BL, Silverman MM (1996). Beyond the Tower of Babel: a nomenclature for suicidology. Suicide Life Threat Behav 26: 237-252.
25. Perlis RH (2007). Cytochrome P450 genotyping and antidepressants. BMJ 334: 759.
26. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP (2009). Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 65: 785-791.
27. Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW et al (2005). Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 25: 427-434.
28. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM et al (2003). Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 54: 879-883.
29. Perlis RH, Moorjani P, Fagerness J, Purcell S, Trivedi MH, Fava M et al (2008). Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 33: 2810-2819.
30. Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH et al (2007). Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 64: 689-697.
31. Petersen T, Dording C, Neault NB, Kornbluh R, Alpert JE, Nierenberg AA et al (2002). A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 26: 177-187.
32. Research AfHCPa (1993). Depression in Primary Care. Vol 2. Treatment of Major Depression. Clinical Practice Guideline, No. 5. (AHCPR publication no. 93-0550.). U.S. Dept. of Health and Human Services: Rockville, MD.
33. Revicki DA, Brown RE, Palmer W, Bakish D, Rosser WW, Anton SF et al (1995). Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics 8: 524-540.
34. Revicki DA, Wood M (1998). Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 48: 25-36.
35. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA et al (2004). Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25: 119-142.
36. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006a). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917.
37. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al (2006b). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354: 1231-1242.
38. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME (2005). Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 62: 37-45.
39. Schaffer A, Levitt AJ, Hershkop SK, Oh P, MacDonald C, Lanctot K (2002). Utility scores of symptom profiles in major depression. Psychiatry Res 110: 189-197.
40. Serretti A, Cusin C, Rausch JL, Bondy B, Smeraldi E (2006). Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Res 145: 61-65.
41. Simon GE, Savarino J, Operskalski B, Wang PS (2006). Suicide risk during antidepressant treatment. Am J Psychiatry 163: 41-47.
42. Simon GE, Von Korff M, Rutter CM, Peterson DA (2001). Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry 58: 395-401.
43. Somanath CP, Jain S, Reddy YC (2002). A family study of early-onset bipolar I disorder. J Affect Disord 70: 91-94.
44. Staples J (2007). Considerations in the commercialization of genomic inventions. Available at http://people.genome.duke.edu/Bmerri034/CVGenomics/ Slides/Staples.pdf. Accessed on 1 October 2007.
45. Sullivan PW, Lawrence WF, Ghushchyan V (2005). A national catalog of preference-based scores for chronic conditions in the United States. Med Care 43: 736-749.
46. The International HapMap Consortium (2003). The International HapMap Project. Nature 426: 789-796.
47. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
48. US Department of Veterans Affairs Health Economic Resource Center: http://www.herc.research.va.gov/resources/faq-a01.asp.
49. Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A (2001). The cost-utility of screening for depression in primary care. Ann Intern Med 134: 345-360.
50. Wang PS, Patrick A, Avorn J, Azocar F, Ludman E, McCulloch J et al (2006). The costs and benefits of enhanced depression care to employers. Arch Gen Psychiatry 63: 1345-1353.
51. Wang PS, Simon GE, Avorn J, Azocar F, Ludman EJ, McCulloch J et al (2007). Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA 298: 1401-1411.
52. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996). Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276: 1253-1258.
53. Wells KB, Schoenbaum M, Duan N, Miranda J, Tang L, Sherbourne C (2007). Cost-effectiveness of quality improvement programs for patients with subthreshold depression or depressive disorder. Psychiatr Serv 58: 1269-1278.
54. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS (2002). Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 22: 417-430.
55. Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM et al (2006). Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 103: 15124-15129.